Skip to main content
PMC home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2020 Apr 21;14(2):117–125. doi: 10.1007/s11684-020-0773-x

Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies

Guangbiao Zhou 1,✉, Saijuan Chen 2, Zhu Chen 2,✉
PMCID: PMC7171433  PMID: 32318975

Abstract

Since the outbreak of the COVID-19 pandemic in early December 2019, 81 174 confirmed cases and 3242 deaths have been reported in China as of March 19, 2020. The Chinese people and government have contributed huge efforts to combat this disease, resulting in significant improvement of the situation, with 58 new cases (34 were imported cases) and 11 new deaths reported on March 19, 2020. However, as of March 19, 2020, the COVID-19 pandemic continues to develop in 167 countries/territories outside of China, and 128 665 confirmed cases and 5536 deaths have been reported, with 16 498 new cases and 817 new deaths occurring in last 24 hours. Therefore, the world should work together to fight against this pandemic. Here, we review the recent advances in COVID-19, including the insights in the virus, the responses of the host cells, the cytokine release syndrome, and the therapeutic approaches to inhibit the virus and alleviate the cytokine storm. By sharing knowledge and deepening our understanding of the virus and the disease pathogenesis, we believe that the community can efficiently develop effective vaccines and drugs, and the mankind will eventually win this battle against this pandemic.

Keywords: COVID-19, SARS-CoV-2, pathogenesis, evidence-based medicine, control and therapeutic strategies

Acknowledgements

This work was supported by the Key Project of the National Natural Science Foundation of China (No. 81830093), the CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2019-I2M-1-003), Double First-Class Project (No. WF510162602) and State Key Laboratory of Medical Genomics of Shanghai Jiao Tong University, Overseas Expertise Introduction Project for Discipline Innovation (111 Project) (No. B17029). The study sponsors had no role in the design of the study; the data collection, analysis, or interpretation; the writing of the article; or the decision to submit for publication.

Compliance with ethics guidelines

Guangbiao Zhou, Saijuan Chen, and Zhu Chen declare no conflict of interests. This manuscript does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.

Contributor Information

Guangbiao Zhou, Email: gbzhou@ioz.ac.cn.

Zhu Chen, Email: zchen@stn.sh.cn.

References

  • 1.Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) 2020. [Google Scholar]
  • 3.World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report-59. 2020. [Google Scholar]
  • 4.World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report-37. 2020. [Google Scholar]
  • 5.Zhang Y, Cao D. China Daily. 2020. Wuhan to close its largest makeshift hospital. [Google Scholar]
  • 6.World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19-11 March 2020. 2020. [Google Scholar]
  • 7.Kannan S, Shaik Syed Ali P, Sheeza A, Hemalatha K. COVID-19 (novel coronavirus 2019) — recent trends. Eur Rev Med Pharmacol Sci. 2020;24(4):2006–2011. doi: 10.26355/eurrev_202002_20378. [DOI] [PubMed] [Google Scholar]
  • 8.Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. doi: 10.1038/s41422-020-0282-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Tang X, Wu C, Li X, Song Y, Yao X, Wu X, Duan Y, Zhang H, Wang Y, Qian Z, Cui J, Lu J. Natl Sci Rev. 2020. On the origin and continuing evolution of SARS-CoV-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Maclean OA, Orton R, Singer J, Robertson DL. Response to “On the origin and continuing evolution of SARS-CoV-2”. 2020. [Google Scholar]
  • 11.Zhang L, Yang J-R, Zhang Z, Lin Z. medRxiv. 2020. Genomic variations of SARS-CoV-2 suggest multiple outbreak sources of transmission. [Google Scholar]
  • 12.Ceraolo C, Giorgi FM. Genomic variance of the 2019-nCoV coronavirus. J Med Virol. 2020;92:522–528. doi: 10.1002/jmv.25700. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Wu A, Niu P, Wang L, Zhou H, Zhao X, Wang W, et al. bioRxiv. 2020. Mutations, recombination and insertion in the evolution of 2019-nCoV. [Google Scholar]
  • 14.Yu WB, Tang GD, Zhang L, Corlett RT. ChinaXiv. 2020. Decoding evolution and transmissions of novel pneumonia coronavirus using the whole genomic data. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. Nat Med. 2020. The proximal origin of SARS-CoV-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Liu H, Wu C, Yang Y, Liu Y, Zhang P, Wang Y, Wang Q, et al. ChinaXiv. 2020. Furin, a potential therapeutic target for COVID-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. Cell. 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Front Med. 2020. The single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7(3):226–236. doi: 10.1038/nrmicro2090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574. doi: 10.1016/S0140-6736(20)30251-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi: 10.1016/S0140-6736(20)30211-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061. doi: 10.1001/jama.2020.1585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS. N Engl J Med. 2020. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. medRxiv. 2020. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. medRxiv. 2020. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19) [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Zhang Z, Li X, Zhang W, Shi ZL, Zheng Z, Wang T. Virol Sin. 2020. Clinical features and treatment of 2019-nCov pneumonia patients in Wuhan: report of a couple cases. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Wang W, He J, Lie P, Huang L, Wu S, Lin Y, et al. medRxiv. 2020. The definition and risks of cytokine release syndrome-like in 11 COVID-19-infected pneumonia critically ill patients: disease characteristics and retrospective analysis. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Nazinitsky A, Rosenthal KS. Cytokine storms: systemic disasters of infectious diseases. Infect Dis Clin Pract. 2010;18(3):188–192. doi: 10.1097/IPC.0b013e3181d2ee41. [DOI] [Google Scholar]
  • 29.Chatenoud L, Ferran C, Reuter A, Legendre C, Gevaert Y, Kreis H, Franchimont P, Bach JF. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-γ [corrected] N Engl J Med. 1989;320(21):1420–1421. doi: 10.1056/NEJM198905253202117. [DOI] [PubMed] [Google Scholar]
  • 30.Behrens EM. Cytokines in cytokine storm syndrome. In: Cron RQ, Behrens EM, editors. Cytokine Storm Syndrome. Cham: Springer International Publishing; 2019. pp. 197–207. [Google Scholar]
  • 31.Okabayashi T, Kariwa H, Yokota S, Iki S, Indoh T, Yokosawa N, Takashima I, Tsutsumi H, Fujii N. Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections. J Med Virol. 2006;78(4):417–424. doi: 10.1002/jmv.20556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Teijaro JR, Walsh KB, Cahalan S, Fremgen DM, Roberts E, Scott F, Martinborough E, Peach R, Oldstone MB, Rosen H. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell. 2011;146(6):980–991. doi: 10.1016/j.cell.2011.08.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529–539. doi: 10.1007/s00281-017-0629-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J, et al. medRxiv. 2020. The potential role of IL-6 in monitoring severe case of coronavirus disease 2019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Yu L, Tong Y, Shen G, Fu A, Lai Y, Zhou X, et al. medRxiv. 2020. Immunodepletion with hypoxemia: a potential high risk subtype of coronavirus disease 2019. [Google Scholar]
  • 36.Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J W FS. Lancet Respir Med. 2020. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, et al. bioRxiv. 2020. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. [Google Scholar]
  • 38.Huang KJ, Su IJ, Theron M, Wu YC, Lai SK, Liu CC, Lei HY. An interferon-g-related cytokine storm in SARS patients. J Med Virol. 2005;75(2):185–194. doi: 10.1002/jmv.20255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Luo W, Yu H, Gou J, Li X, Sun Y, Li J, Liu L. Preprints. 2020. Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19) p. 2020020407. [Google Scholar]
  • 40.Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273. doi: 10.1038/s41586-020-2012-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Anastassopoulou C, Russo L, Tsakris A, Siettos C. medRxiv. 2020. Data-based analysis, modelling and forecasting of the novel coronavirus (2019-nCoV) outbreak. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G L T W J, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. N Engl J Med. 2020. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Chin J Epidemiol (Zhonghua Liu Xing Bing Xue Za Zhi) 2020;41(2):145–151. [Google Scholar]
  • 44.Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Proc Natl Acad Sci USA. 2020. The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Chen L, Xiong J, Bao L, Shi Y. Lancet Infect Dis. 2020. Convalescent plasma as a potential therapy for COVID-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, Diaz G, Cohn A, Fox L, Patel A, Gerber SI, Kim L, Tong S, Lu X, Lindstrom S, Pallansch MA, Weldon WC, Biggs HM, Uyeki TM, Pillai SK. Washington State 2019-nCoV Case Investigation Team. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929–936. doi: 10.1056/NEJMoa2001191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi: 10.1056/NEJMoa2001017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Staedtke V, Bai RY, Kim K, Darvas M, Davila ML, Riggins GJ, Rothman PB, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S. Disruption of a self-amplifying catecholamine loop reduces cyto-kine release syndrome. Nature. 2018;564(7735):273–277. doi: 10.1038/s41586-018-0774-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.London NR, Zhu W, Bozza F S M, Greif DM, Sorensen LK, et al. Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza. Sci Transl Med. 2010;2(23):23. doi: 10.1126/scitranslmed.3000678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Liu X, Li Z, Liu S, Chen Z, Zhao Z, Huang YY, et al. medRxiv. 2020. Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction. [Google Scholar]
  • 51.Pfaender S, Mar KB, Michailidis E, Kratzel A, Hirt D, V’kovski P, et al. bioRxiv. 2020. LY6E impairs coronavirus fusion and confers immune control of viral disease. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, Wang Q, Xu Y, Li M, Li X, Zheng M, Chen L, Li H. Acta Pharm Sin B. 2020. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Rimanshee A, Amit D, Vishal P, Mukesh K. ChemRxiv. 2020. Potential inhibitors against papain-like protease of novel coronavirus (SARS-CoV-2) from FDA approved drugs. [Google Scholar]
  • 54.Tahirul Qamar M, Alqahtani S, Alamri M, Chen L. Preprints. 2020. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants; p. 2020020193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. N Engl J Med. 2020. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Frontiers of Medicine are provided here courtesy of Nature Publishing Group

RESOURCES